III期子宫内膜癌三明治与序贯放化疗的生存结局与时间毒性:按分子分层的真实世界研究
该真实世界研究分析119例III期子宫内膜癌患者,比较三明治方案(化疗-放疗-化疗,n=77)与序贯方案(化疗-放疗,n=42)的生存结局与时间毒性,并按p53和MMR状态分层。两组总生存和无进展生存无显著差异,但三明治组总治疗时间更短、放疗启动更早,且在pMMR和p53突变亚组中显示获益趋势,低级别腹泻更常见但≥3级不良事件罕见且相似。
要点
- 三明治与序贯方案在III期子宫内膜癌中总生存和无进展生存无显著差异。
- 三明治组总治疗时间更短(198.0 vs 223.0天)且放疗启动更早(77.0 vs 171.5天)。
- pMMR和p53突变亚组中三明治方案显示无进展生存或复发时间获益。
核心结论
- 三明治方案在III期子宫内膜癌中不劣于序贯方案的总生存和无进展生存,同时减少时间毒性并更早启动盆腔放疗。
- 该时间优化序贯策略可能对高危分子亚型(p53突变/pMMR)尤其有益,支持分子导向的辅助治疗范式。
研究设计与样本
- 真实世界研究,分析2015-2025年间119例III期子宫内膜癌患者,序贯组42例,三明治组77例。
- 主要终点包括总生存、无进展生存、相对剂量强度和总治疗时间,并按p53和MMR状态分层。
主要发现
- 两组总生存(P = .73)和无进展生存(P = .93)无显著差异。
- 亚组分析中,三明治方案在pMMR肿瘤中无进展生存获益(P = .026),在p53突变肿瘤中至复发时间改善(P = .034)。
- 三明治组中位总治疗时间显著更短(198.0 vs 223.0天;P < .001),放疗启动更早(77.0 vs 171.5天;P < .001)。
- 化疗剂量强度两组相当(P = .878);低级别腹泻在三明治组更常见(43% vs 21%;P = .027),≥3级不良事件罕见且两组相似。
临床怎么用
- 对于III期子宫内膜癌,可考虑采用三明治方案以减少总治疗时间和更早启动盆腔放疗,而不牺牲化疗剂量强度。
- 对pMMR或p53突变高危分子亚型患者,三明治方案可能带来额外生存获益,支持分子分型指导的辅助治疗决策。
局限性
- 本研究为真实世界回顾性研究,样本量有限(共119例),可能存在选择偏倚和混杂因素。
- 亚组分析样本量较小,分子分层后的结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the survival outcomes of Sandwich (Chemo-RT-Chemo) versus Sequential (Chemo-RT) therapy in Stage III endometrial cancer, focusing on the interplay between treatment intervals, time toxicity, and molecular classification. METHODS: We analyzed 119 patients with Stage III EC (2015-2025) receiving either Sequential (n = 42) or Sandwich (n = 77) regimens. Endpoints included overall survival (OS), progression-free survival (PFS), relative dose intensity (RDI), and overall treatment time (OTT). Outcomes were stratified by p53 and MMR status. RESULTS: Among 119 patients (42 Sequential, 77 Sandwich) with well-balanced characteristics, no significant differences were observed in OS (P = .73) or PFS (P = .93). However, subgroup analysis favored the Sandwich regimen in pMMR tumors (PFS benefit, P = .026) and p53-mutant tumors (improved time-to-recurrence, P = .034). Regarding time toxicity, the Sandwich cohort demonstrated significantly shorter median overall treatment time (198.0 vs. 223.0 days; P < .001) and earlier radiotherapy initiation (77.0 vs. 171.5 days; P < .001). Chemotherapy dose intensity remained comparable (P = .878). While low-grade diarrhea was more frequent in the Sandwich arm (43% vs. 21%; P = .027), grade≧3 adverse events were rare and similar between groups. CONCLUSIONS: The Sandwich regimen offers a dual advantage: it reduces patient time toxicity and ensures earlier pelvic control without sacrificing chemotherapy intensity. This optimized temporal sequencing appears particularly beneficial for high-risk molecular subtypes (p53-mutant/pMMR) and supports the paradigm of molecular-directed adjuvant therapy.
引用
- Lee KY, Tseng TH, Chang WC, et al. Survival outcomes and time toxicity of Sandwich versus Sequential chemoradiation in Stage III endometrial cancer: A real-world study stratified by molecular classification. Gynecol Oncol. 2026. PMID: 41734477. doi:10.1016/j.ygyno.2026.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。